These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35438175)

  • 1. Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada.
    Skowronski DM; Febriani Y; Ouakki M; Setayeshgar S; El Adam S; Zou M; Talbot D; Prystajecky N; Tyson JR; Gilca R; Brousseau N; Deceuninck G; Galanis E; Fjell CD; Sbihi H; Fortin E; Barkati S; Sauvageau C; Naus M; Patrick DM; Henry B; Hoang LMN; De Wals P; Garenc C; Carignan A; Drolet M; Jassem AN; Sadarangani M; Brisson M; Krajden M; De Serres G
    Clin Infect Dis; 2022 Nov; 75(11):1980-1992. PubMed ID: 35438175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada.
    Skowronski DM; Setayeshgar S; Zou M; Prystajecky N; Tyson JR; Sbihi H; Fjell CD; Galanis E; Naus M; Patrick DM; El Adam S; Ahmed MA; Kim S; Henry B; Hoang LMN; Sadarangani M; Jassem AN; Krajden M
    J Infect Dis; 2022 Aug; 226(1):485-496. PubMed ID: 35084500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada.
    Skowronski DM; Setayeshgar S; Zou M; Prystajecky N; Tyson JR; Galanis E; Naus M; Patrick DM; Sbihi H; El Adam S; Henry B; Hoang LMN; Sadarangani M; Jassem AN; Krajden M
    Clin Infect Dis; 2022 Apr; 74(7):1158-1165. PubMed ID: 34244723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From Québec, Canada.
    Carazo S; Talbot D; Boulianne N; Brisson M; Gilca R; Deceuninck G; Brousseau N; Drolet M; Ouakki M; Sauvageau C; Barkati S; Fortin É; Carignan A; De Wals P; Skowronski DM; De Serres G
    Clin Infect Dis; 2022 Aug; 75(1):e805-e813. PubMed ID: 34460902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study.
    Nasreen S; Febriani Y; Velásquez García HA; Zhang G; Tadrous M; Buchan SA; Righolt CH; Mahmud SM; Janjua NZ; Krajden M; De Serres G; Kwong JC
    Clin Infect Dis; 2023 Feb; 76(4):640-648. PubMed ID: 35974428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12-17 Years, by Dosing Interval and Duration.
    Ionescu IG; Skowronski DM; Sauvageau C; Chuang E; Ouakki M; Kim S; De Serres G
    J Infect Dis; 2023 Apr; 227(9):1073-1083. PubMed ID: 36645782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada.
    El Adam S; Zou M; Kim S; Henry B; Krajden M; Skowronski DM
    Open Forum Infect Dis; 2022 May; 9(5):ofac178. PubMed ID: 35531384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of COVID-19 vaccines.
    Graña C; Ghosn L; Evrenoglou T; Jarde A; Minozzi S; Bergman H; Buckley BS; Probyn K; Villanueva G; Henschke N; Bonnet H; Assi R; Menon S; Marti M; Devane D; Mallon P; Lelievre JD; Askie LM; Kredo T; Ferrand G; Davidson M; Riveros C; Tovey D; Meerpohl JJ; Grasselli G; Rada G; Hróbjartsson A; Ravaud P; Chaimani A; Boutron I
    Cochrane Database Syst Rev; 2022 Dec; 12(12):CD015477. PubMed ID: 36473651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
    Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland.
    Kerr S; Vasileiou E; Robertson C; Sheikh A
    J Glob Health; 2022 Jul; 12():05025. PubMed ID: 35802764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
    Andrews N; Tessier E; Stowe J; Gower C; Kirsebom F; Simmons R; Gallagher E; Thelwall S; Groves N; Dabrera G; Myers R; Campbell CNJ; Amirthalingam G; Edmunds M; Zambon M; Brown K; Hopkins S; Chand M; Ladhani SN; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Jan; 386(4):340-350. PubMed ID: 35021002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV.
    Chambers C; Samji H; Cooper CL; Costiniuk CT; Janjua NZ; Kroch AE; Arbess G; Benoit AC; Buchan SA; Chung H; Kendall CE; Kwong JC; Langlois MA; Lee SM; Mbuagbaw L; McCullagh J; Moineddin R; Nambiar D; Walmsley S; Anis AH; Burchell AN;
    AIDS; 2022 Dec; 36(15):F17-F26. PubMed ID: 36254892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data.
    Kumwichar P; Poonsiri C; Botwright S; Sirichumroonwit N; Loharjun B; Thawillarp S; Cheewaruangroj N; Chokchaisiripakdee A; Teerawattananon Y; Chongsuvivatwong V
    JMIR Public Health Surveill; 2024 Mar; 10():e48255. PubMed ID: 38441923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
    Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
    J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.